Stock Market & Financial Investment News

News Breaks February 25, 2013 18:02 EDT MNOV FDA grants fast track designation for MedicNova's MN-166 MediciNova and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced that it has received Fast Track designation from the U.S. FDA for MN-166 (ibudilast) for the treatment of methamphetamine dependence. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious diseases and have the potential to fill an unmet medical need. An important feature of the FDA's Fast Track program is that it emphasizes early and frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval. News For MNOV From The Last 14 Days Check below for free stories on MNOV the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. There are no results for MNOV Sign up for a free trial to see the rest of the stories you've been missing.